Grant ID RP140402
Awarded On August 20, 2014
Title Novel Targets for Acute Myeloid Leukemia Treatment
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas Southwestern Medical Center
Principal Investigator/Program Director Chengcheng Zhang
Cancer Sites Leukemia
Contracted Amount $900,000
Lay Summary

Acute myeloid leukemia (AML) is the most common acute leukemia affecting adults. Despite continuous treatment, the majority of the patients relapse within 5 years. Leukemia stem cells (LSCs) may be responsible for the relapse of disease following a remission brought about by conventional chemotherapy, and new molecular targets and therapeutic approaches need to be identified to effectively inhibit LSC activity. Our research has indicated that the inhibitory receptor LAIR1 supports the self-renewal and survival of human leukemia cells. We found that LAIR1 is highly expressed on cells from AML patients and that LAIR1+ primary human AML cells are enriched for AML stem cell (AML-SC) activity. In...

Read More